Results 21 to 30 of about 19,417 (208)

Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma

open access: yesInternational Journal of Cancer, EarlyView.
What's New? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg   +5 more
wiley   +1 more source

Is Micronucleus Assay a Suitable Biomarker for Evaluating the Cancer Risk in Professionals Exposed to Antineoplastic Drugs? A Systematic Review

open access: yesJournal of Applied Toxicology, EarlyView.
ABSTRACT The widespread use of antineoplastic drugs in cancer treatment has led to significant concerns regarding the potential health risks posed to healthcare professionals involved in the preparation, administration, and handling of these chemical compounds, including genotoxicity.
Thiago Guedes Pinto   +6 more
wiley   +1 more source

Low Dose Pegylated Interferon Alpha as a First‐Line Treatment for Necrobiotic Xanthogranuloma

open access: yesJEADV Clinical Practice, EarlyView.
ABSTRACT Necrobiotic xanthogranuloma (NXG) is a rare, progressive granulomatous disorder frequently associated with monoclonal gammopathy, particularly monoclonal gammopathy of undetermined significance (MGUS). It typically presents with indurated to ulcerative yellowish plaques or nodules, often with ocular involvement.
Ishana Dixit   +2 more
wiley   +1 more source

The DiSC assay - A cost-effective guide to treatment for chronic lymphocytic leukemia? [PDF]

open access: yes, 1999
The differential staining cytotoxicity (DISC) assay involves in vitro drug panel testing against patient tumor cells to identify optimal therapy. This observational study investigated whether DISC assay guided treatment could improve outcome in patients ...
Bosanquet, A.G.   +3 more
core   +1 more source

B‐Cell Chronic Lymphocytic Leukemia in a Cat

open access: yesVeterinary Clinical Pathology, EarlyView.
ABSTRACT Background An 8.8‐year‐old male neutered Persian cat was presented with a history of recent intermittent mild lethargy, hyporexia, and weight loss. Physical examination revealed pale mucous membranes, an enlarged right mandibular lymph node, and organomegaly suspected to be an enlarged spleen.
James Andre Mori   +3 more
wiley   +1 more source

Chemical genetics analysis of an aniline mustard anticancer agent reveals complex I of the electron transport chain as a target [PDF]

open access: yes, 2011
Supplementary information is available at the Journal of Biological Chemistry website.The antitumor agent 11β (CAS 865070-37-7), consisting of a DNA-damaging aniline mustard linked to an androgen receptor (AR) ligand, is known to form covalent DNA ...
Cossarizza   +30 more
core   +1 more source

Imaging findings and clinical outcome in three cats with possible inflammatory ureteritis

open access: yesVeterinary Record Case Reports, Volume 14, Issue 1, February 2026.
Abstract Three adult cats presented to our institution for evaluation of non‐specific clinical signs and azotaemia. All cats had sonographic evidence of renal pelvic and ureteral dilation, concerning for a ureteral obstruction without a definitive mechanical cause identified. Anti‐inflammatory doses of corticosteroids were administered over an extended
Elisa L. Heacock   +3 more
wiley   +1 more source

Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation. [PDF]

open access: yes, 2001
Ligation of the cell-surface Fas molecule by its ligand (Fas-L) or agonistic anti-Fas monoclonal antibodies results in the cleavage and activation of the cysteine protease procaspase 8 followed by the activation of procaspase 3 and by apoptosis.
Folarin, NI   +8 more
core  

Cardiovascular Challenges in Chronic Lymphocytic Leukemia (CLL) Patients Undergoing Bruton Tyrosine Kinase (BTK) Inhibitor Therapy

open access: yesEuropean Journal of Haematology, Volume 116, Issue 2, Page 104-115, February 2026.
ABSTRACT Background/Objectives Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second‐generation BTKis offer improved target specificity, yet CV risks persist.
Stefano Oliva, Stefano Molica
wiley   +1 more source

Home - About - Disclaimer - Privacy